Risk of osteoporosis and fracture incidence in patients on antipsychotic medication

Expert Opinion on Drug Safety

Volumn 10, Issue 4, 2011, Pages 575-602

  Graham, Simon Matthew ^a   Howgate, Daniel ^a   Anderson, William ^a   Howes, Claire ^a   Heliotis, Manolis ^b   Mantalaris, Athanassios ^c   Tsiridis, Eleftherios ^a,c,d   Tsapakis, Evangelia ^e,f  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b NORTHWICK PARK HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f 'Aghios Charalambos' Mental Health Centre   (Greece)

Author keywords

antipsychotic drugs; bone; fracture; osteoporosis

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CABERGOLINE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; QUINAGOLIDE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE;

BONE DENSITY; BONE METABOLISM; DRUG EFFECT; EMBASE; FRACTURE; HOMEOSTASIS; HUMAN; HYPERPROLACTINEMIA; IN VIVO STUDY; MEDLINE; MONOTHERAPY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; PROLACTIN BLOOD LEVEL; PSYCINFO; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; FRACTURES, BONE; HUMANS; INCIDENCE; OSTEOPOROSIS; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 79958803744     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.560112     Document Type: Review

References (132)

1. Hugenholtz GW, Heerdink ER, van Staa TP, et al. Risk of hip/femur fractures in patients using antipsychotics. Bone 2005;37(6):864-70 (Pubitemid 41773497)
2. Schlosser R, Grunder G, Anghelescu I, et al. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002;46(1):33-40 (Pubitemid 35002316)
3. Neutel CI, Perry S, Maxwell S, et al. Medication use and risk of falls. Pharmacoepidemiol Drug Saf 2002;11(2):97-104 (Pubitemid 34464329)
4. Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28(Suppl 2):55-68 (Pubitemid 36332229)
5. Howard L, Kirkwood G, Leese M, et al. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007;190:129-34
6. Rey-Sanchez P, Lavado-Garcia JM, Canal-Macias ML, et al. Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum Psychopharmacol 2009;24(1):49-54
7. Charoenphandhu N, Teerapornpuntakit J, Methawasin M, et al. Prolactin decreases expression of Runx2, osteoprotegerin, and RANKL in primary osteoblasts derived from tibiae of adult female rats. Can J Physiol Pharmacol 2008;86(5):240-8 (Pubitemid 351705484)
8. Murphy BP, Chung YC, Park TW, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006;88(1-3):5-25 (Pubitemid 44693240)
9. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22(3):787-97
10. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989;99(Suppl):S18-27 (Pubitemid 19244134)
11. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001;158(3):360-9 (Pubitemid 32205190)
12. Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 2002;14(3):163-73 (Pubitemid 36172565)
13. Kane JM, Freeman HL. Towards more effective antipsychotic treatment. Br J Psychiatry Suppl 1994;(25):22-31 (Pubitemid 24331670)
14. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl) 1996;124(1-2):2-34 (Pubitemid 26111436)
15. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-9 (Pubitemid 34680462)
16. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28(8): 1400-11 (Pubitemid 41070874)
17. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19(1):57-61 (Pubitemid 29047332)
18. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64(20):2291-314 (Pubitemid 39388605)
19. Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19(3):225-68 (Pubitemid 29117815)
20. Jaber M, Robinson SW, Missale C, et al. Dopamine receptors and brain function. Neuropharmacology 1996;35(11):1503-19 (Pubitemid 27026480)
21. Muller EE, Locatelli V, Cella S, et al. Prolactin-lowering and -releasing drugs. Mechanisms of action and therapeutic applications. Drugs 1983;25(4):399-432 (Pubitemid 13112225)
22. Cowen PJ, Anderson IM, Gartside SE. Endocrinological responses to 5-HT. Ann N Y Acad Sci 1990;600:250-7;discussion 257-9
23. Van de Kar LD, Javed A, Zhang Y, et al. 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 2001;21(10):3572-9 (Pubitemid 32422821)
24. Meaney AM, OKeane V. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci 2002;71(9):979-92 (Pubitemid 34667104)
25. Bressan RA, Erlandsson K, Spencer EP, et al. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology (Berl) 2004;175(3):367-73 (Pubitemid 39361925)
26. Dickson RA, Dalby JT, Williams R, et al. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995;152(7):1102-3
27. Breier AF, Malhotra AK, Su TP, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999;156(2):294-8 (Pubitemid 29077121)
28. Markianos M, Hatzimanolis J, Lykouras L. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol. Eur Arch Psychiatry Clin Neurosci 2001;251(3):141-6 (Pubitemid 32963107)
29. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999.;35(Suppl):S67-73 (Pubitemid 29133027)
30. Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003;182:199-204 (Pubitemid 36286731)
31. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002;302(3):1129-34 (Pubitemid 34920235)
32. Protais P, Hermier C, Costentin J. The discriminant dopamine antagonist property of benzamides is observed at various times after their systemic or intracerebroventricular administration. Neuropharmacology 1985;24(9):861-7 (Pubitemid 16256929)
33. Rao ML, Gross G, Strebel B, et al. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry 1994;35(3):151-63 (Pubitemid 24078480)
34. Mihara K, Suzuki A, Kondo T, et al. Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet 2001;105(3):271-4 (Pubitemid 32410901)
35. Young RM, Lawford BR, Barnes M, et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 2004;185:147-51 (Pubitemid 39061458)
36. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33(4):227-35 (Pubitemid 23091497)
37. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000;57(6):553-9 (Pubitemid 30349435)
38. Poole KE, Compston JE. Osteoporosis and its management. BMJ 2006;333(7581):1251-6 (Pubitemid 46043106)
39. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38(2 Suppl 1):S4-9 (Pubitemid 43190767)
40. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359(9319):1761-7
41. Becker D, Liver O, Mester R, et al. Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 2003;64(7):761-6 (Pubitemid 36897211)
42. Biller BM, Baum HB, Rosenthal DI, et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992;75(3):692-7
43. Meaney AM, Smith S, Howes OD, et al. Effects of long-term prolactinraising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004;184:503-8 (Pubitemid 38725710)
44. Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003;28(Suppl 2):97-108 (Pubitemid 36332232)
45. Kishimoto T, Watanabe K, Shimada N, et al. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry 2008;69(3):385-91 (Pubitemid 351549390)
46. Knegtering H, van der Moolen AE, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003;28(Suppl 2):109-23 (Pubitemid 36335820)
47. OKeane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008;22(Suppl 2):70-5
48. Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med 1986;314(26):1676-86 (Pubitemid 16097845)
49. Bataille-Simoneau N, Gerland K, Chappard D, et al. Expression of prolactin receptors in human osteosarcoma cells. Biochem Biophys Res Commun 1996;229(1):323-8 (Pubitemid 27013751)
50. Seriwatanachai D, Krishnamra N, van Leeuwen JP. Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralization. J Cell Biochem 2009;107(4):677-85
51. Nixon MF, Ibrahim T, Johari Y, et al. Managing osteoporosis in patients with fragility fractures: did the British Orthopaedic Association guidelines have any impact? Ann R Coll Surg Engl 2007;89(5):504-9
52. Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 2007;21(7):768-73 (Pubitemid 47437921)
53. Meltzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976;33(3):279-86
54. Kuruvilla A, Peedicayil J, Srikrishna G, et al. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992;19(9):603-6
55. Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm 1992;11(10):851-6
56. Zelaschi NM, Delucchi GA, Rodriguez JL. High plasma prolactin levels after long-term neuroleptic treatment. Biol Psychiatry 1996;39(10):900-1 (Pubitemid 26163537)
57. Smith S, Wheeler MJ, Murray R, et al. The effects of antipsychotic- induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002;22(2):109-14 (Pubitemid 34289384)
58. Hummer M, Malik P, Gasser RW, et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005;162(1):162-7 (Pubitemid 40095686)
59. Johnson GF, Hunt GE. The effect of thioridazine on prolactin levels in acutely schizophrenic patients: challenge-dose and steady-state levels. Aust N Z J Psychiatry 1980;14(2):127-31 (Pubitemid 11197944)
60. Chouinard G, Annable L, Jones BD, et al. Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system. Acta Psychiatr Scand 1981;64(5):353-62 (Pubitemid 12172426)
61. Turkington RW. Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Arch Intern Med 1972;130(3):349-54
62. Wistedt B, Wiles D, Kolakowska T. Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet 1981;1(8230):1163 (Pubitemid 11105817)
63. Turrone P, Kapur S, Seeman MV, et al. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002;159(1):133-5
64. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156(2):286-93 (Pubitemid 29077120)
65. Brunelleschi S, Zeppegno P, Risso F, et al. Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients. Pharmacol Res 2003;48(4):405-9 (Pubitemid 36945339)
66. David SR, Taylor C, Kinon BJ, et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22(9):1085-96
67. Kaneda Y, Ohmori T. Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation. Int J Neuropsychopharmacol 2003;6(3):247-52 (Pubitemid 37248003)
68. Knegtering R, Baselmans P, Castelein S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005;162(5):1010-12 (Pubitemid 40676220)
69. Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994;55(Suppl):13-17 (Pubitemid 24179364)
70. Zhang XY, Zhou DF, Yuan CL, et al. Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Psychiatry Res 2002;109(3):297-302 (Pubitemid 34311986)
71. Eberhard J, Lindstrom E, Holstad M, et al. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand 2007;115(4):268-76 (Pubitemid 46425745)
72. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151(6):825-35
73. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005;162(5):947-53 (Pubitemid 40676208)
74. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85(4):295-305
75. Zhang XY, Zhou DF, Cao LY, et al. Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. Psychopharmacology (Berl) 2005;178(1):35-40 (Pubitemid 40298689)
76. Konarzewska B, Wolczynski S, Szulc A, et al. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology 2009;34(1):129-39
77. Potkin SG, Gharabawi GM, Greenspan AJ, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res 2006;85(1-3):254-65 (Pubitemid 43947539)
78. Mullen J, Jibson MD, Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 2001;23(11):1839-54 (Pubitemid 33121972)
79. Fric M, Laux G. [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine]. Psychiatr Prax 2003;30(Suppl 2):97-101
80. Paparrigopoulos T, Liappas J, Tzavellas E, et al. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(1):92-6 (Pubitemid 44959254)
81. Kopecek M, Bares M, Svarc J, et al. Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett 2004;25(6):419-22 (Pubitemid 40227970)
82. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14(2):87-96 (Pubitemid 26053226)
83. Beasley CM, Hamilton SH Jr, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7(2):125-37 (Pubitemid 27240346)
84. Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26(1):41-54 (Pubitemid 27372056)
85. Fulton B, Goa KL. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997;53(2):281-98 (Pubitemid 27073117)
86. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155(7):921-8 (Pubitemid 28307604)
87. Lamberts SW, van Koetsveld PM, Hofland LJ. The effect of clozapine on prolactin secretion at the level of the lactotroph. Life Sci 1990;46(14):1013-19 (Pubitemid 20150557)
88. Brown AS, Gewirtz G, Harkavy-Friedman J, et al. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology 1997;17(5):317-25 (Pubitemid 27468169)
89. Henderson DC, Goff DC, Connolly CE, et al. Risperidone added to clozapine: impact on serum prolactin levels. J Clin Psychiatry 2001;62(8):605-8 (Pubitemid 32848163)
90. Markianos M, Hatzimanolis J, Lykouras L. Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. Eur Neuropsychopharmacol 1999;9(6):533-6 (Pubitemid 30089067)
91. Meltzer HY, Goode DJ, Schyve PM, et al. Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979;136(12):1550-5 (Pubitemid 10206621)
92. Pickar D, Owen RR, Litman RE, et al. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992;49(5):345-53
93. Remington G, Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology (Berl) 2000;148(1):3-15 (Pubitemid 30062465)
94. de Leon J, Diaz FJ, Josiassen RC, et al. Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. Eur Arch Psychiatry Clin Neurosci 2004;254(5):318-25 (Pubitemid 39312826)
95. Bunker MT, Marken PA, Schneiderhan ME, et al. Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. J Child Adolesc Psychopharmacol 1997;7(1):65-9 (Pubitemid 27252850)
96. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The seroquel trial 13 study group. Biol Psychiatry 1997;42(4):233-46 (Pubitemid 27325811)
97. Borison RL, Arvanitis LA, Miller BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996;16(2):158-69 (Pubitemid 26141753)
98. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, Seroquel) and haloperidol in schizophrenia. Psychol Med 2000;30(1):95-105 (Pubitemid 30099122)
99. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112(2-3):285-92 (Pubitemid 23278291)
100. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel study group. Arch Gen Psychiatry 1997;54(6):549-57 (Pubitemid 27258553)
101. Buckley PF, Goldstein JM, Emsley RA. Efficacy and tolerability of quetiapine in poorly responsive, chronic schizophrenia. Schizophr Res 2004;66(2-3):143-50 (Pubitemid 38041112)
102. Byerly MJ, Marcus RN, Tran QV, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res 2009;107(2-3):218-22
103. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166(4):391-9 (Pubitemid 36469941)
104. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-71
105. Lee BH, Kim YK. The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(4):658-62
106. Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(8):1978-81
107. Sacchetti E, Galluzzo A, Valsecchi P, et al. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res 2009;110(1-3):80-9
108. Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol 2000;49(Suppl 1):5S-13S (Pubitemid 30151047)
109. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61(2-3):123-36 (Pubitemid 36513927)
110. Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159(2):180-90 (Pubitemid 34126893)
111. Clement-Lacroix P, Ormandy C, Lepescheux L, et al. Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. Endocrinology 1999;140(1):96-105 (Pubitemid 29011146)
112. Coss D, Yang L, Kuo CB, et al. Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab 2000;279(6):E1216-25
113. Seriwatanachai D, Thongchote K, Charoenphandhu N, et al. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 2008;42(3):535-46
114. Ritchie LD, Fung EB, Halloran BP, et al. A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses. Am J Clin Nutr 1998;67(4):693-701 (Pubitemid 28153171)
115. Seriwatanachai D, Charoenphandhu N, Suthiphongchai T, et al. Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol Int 2008;32(9):1126-35
116. Lotinun S, Limlomwongse L, Sirikulchayanonta V, et al. Bone calcium turnover, formation, and resorption in bromocriptine- and prolactin-treated lactating rats. Endocrine 2003;20(1-2):163-70 (Pubitemid 36515201)
117. Puntheeranurak S, Charoenphandhu N, Krishnamra N. Enhanced trabecular-bone calcium deposition in female rats with a high physiological dose of prolactin diminishes after ovariectomy. Can J Physiol Pharmacol 2006;84(10):993-1002
118. Cann CE, Martin M C, Genant HK, et al. Decreased spinal mineral content in amenorrheic women. JAMA 1984;251(5):626-9 (Pubitemid 14221023)
119. Schlechte JA, Sherman B, Martin R. Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 1983;56(6):1120-3 (Pubitemid 13055103)
120. Torring O, Isberg B, Sjoberg HE, et al. Plasma calcitonin, IGF-I levels and vertebral bone mineral density in hyperprolactinemic women during bromocriptine treatment. Acta Endocrinol (Copenh) 1993;128(5):423-7 (Pubitemid 23169454)
121. Di Somma C, Colao A, Di Sarno A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998;83(3):807-13 (Pubitemid 28496451)
122. OKeane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005;25(1):26-31 (Pubitemid 40129379)
123. Abraham G, Halbreich U, Friedman RH, et al. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr Res 2003;59(1):17-18 (Pubitemid 35284489)
124. Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995;57(5):485-91
125. Jung DU, Conley RR, Kelly DL, et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry 2006;67(9):1391-6 (Pubitemid 44583386)
126. Liperoti R, Onder G, Lapane KL, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry 2007;68(6):929-34 (Pubitemid 47015494)
127. Pouwels S, van Staa TP, Egberts AC, et al. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2009;20(9):1499-506
128. Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316(7):363-9 (Pubitemid 17034260)
129. Vestergaard P, Rejnmark L, Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 2006;17(6):807-16 (Pubitemid 43781493)
130. Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. Epidemiol Rev 1997;19(2):244-57 (Pubitemid 28099774)
131. Misra M, Papakostas GI, Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 2004;65(12):1607-18, quiz 1590, 1760-1
132. Renn JH, Yang NP, Chueh CM, et al. Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord 2009;10:1